Da Jan Yang

Functions as a College/University

Develops and discovers novel targeted small molecule drugs

Functions as a College/University

Operates as a biopharmaceutical company that engages in discovering, developing and commercializing of therapies for hematological malignancies

Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group, Inc. is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule and degrader therapies primarily targeting hematologic malignancies and select solid tumors. Ascentage maintains rights to its key assets and has established partnerships with pharmaceutical companies including Takeda, Innovent, AstraZeneca, Merck, and Pfizer, as well as collaborations with research institutions such as Dana-Farber, Mayo Clinic, MD Anderson, and the National Cancer Institute. The company is based in Rockville, MD. The company leverages expertise in structure-based drug design and proprietary platforms to focus on restoring apoptosis and inhibiting oncogenic signaling pathways by targeting proteins such as bcl-2, bcl-xl, iap, mdm2-p53, and tyrosine kinases including bcr-abl1, alk, fak, and ros1. Its lead approved products include olverembatinib, a third-generation bcr-abl1 tyrosine kinase inhibitor for treatment-resistant chronic myeloid leukemia, and lisaftoclax, a novel oral bcl-2 inhibitor for chronic lymphocytic leukemia/small lymphocytic lymphoma after prior therapies. Both drugs are included in the national reimbursement drug list and are undergoing multiple phase III registrational trials cleared by regulatory agencies such as the FDA and EMA. The clinical pipeline also features pelcitoclax, a dual bcl-2/bcl-xl inhibitor for small cell lung cancer; alrizomadlin, an mdm2-p53 inhibitor; apg-2449, a fak/alk/ros1 inhibitor for non-small-cell lung cancer; and apg-3288, a novel btk degrader. The company is conducting over 40 international clinical trials across hematologic malignancies and solid tumors, emphasizing monotherapy and combination regimens.